Mr. Pradeep Ramamurthy Joins OpenGate Capital as Co-Head of Investor Relations
OpenGate Capital, a global private equity firm, announced today that Mr. Pradeep Ramamurthy has joined as Co-Head of Investor Relations. Based in the firm’s Los Angeles office, he will be working with OpenGate’s Founder & CEO, Andrew Nikou as well as Alanna Chaffin, OpenGate’s Co-Head of Investor Relations and Communications, to grow and deepen the firm’s partnerships with institutional investors.
Ramamurthy has nearly a decade of private equity experience with a background in brand-building, product development, and full-cycle investor relations. Prior to joining OpenGate, he advised clients in the US, Asia, and Africa on product development and capital strategy as the Managing Director of Cauvery, a San Francisco-based consulting firm. He was also a Managing Director at The Abraaj Group, a private equity firm that invested across emerging markets. Prior to his private equity career, Ramamurthy served in senior operational and management positions at the White House, US Agency for International Development, and US Intelligence Community.
“I am thrilled to welcome Pradeep into our firm and excited to have him join our team,” said Nikou. “Given his strategic approach, global network, and diverse background, I am confident Pradeep will help OpenGate strengthen and grow its relationships with investors – especially as the current dislocation in global markets both validates and creates opportunity for our investment approach.”
Ramamurthy stated, “The opportunity to join OpenGate at this point in the firm’s evolution is truly exciting. The firm’s one team mindset, global perspective, and track record of finding and creating value in operationally complex situations is compelling and timely. I am looking forward to working with Andrew, Alanna and the entire OpenGate team to share and grow that value proposition with the LP community.”
Ramamurthy has an M.A., Social Science from the University of Chicago, and a B. Sc, International Politics from Georgetown University.
OpenGate Capital’s global team across the US and Europe execute on the firm’s integrated value creation strategy of sourcing, execution and operations which is applied throughout an investment’s life cycle.
About OpenGate Capital
OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation and growth. Established in 2005, OpenGate Capital is headquartered in Los Angeles, California with a European office in Paris, France. OpenGate’s professionals possess the critical skills needed to acquire, transition, operate, build and scale successful businesses. To date, OpenGate Capital, through its legacy and fund investments, has executed more than 30 acquisitions including corporate carve-outs, management buy-outs, special situations and transactions with private sellers across North America and Europe. To learn more about OpenGate, please visit www.opengatecapital.com.
OpenGate Media Contacts
Telephone: +1 (310) 432-7000
OpenGate Business Development Contact
Telephone: +1 (310) 432-7000
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 13:30:00 CEST | Press release
The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na
TIP Trailer Services Announces Appointment of New CFO25.5.2020 10:05:00 CEST | Press release
TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY ® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 08:00:00 CEST | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio
JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 08:00:00 CEST | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine
U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer22.5.2020 22:30:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations. “We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with brain metastases,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “Through a robust clinical development program and ongoing investigations across the NSCLC treatment landscape, Takeda is committed to uncovering solutions for people living with devastating forms of lung cancer in need of new options. We believe this approva
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom